An interventional study of AI-assisted ECG interpretation (PMcardio) in Myocardial Infarction (MI) and Acute Coronary Syndrome (ACS), sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 22nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2025, is one of 24 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 63rd registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:
École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Sites in Switzerland
Ages 18+ · Healthy volunteers
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Novo Nordisk A/S · Sites in Switzerland, Austria, Denmark and 3 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Baris Gencer · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 334 across the 51 interventional studies, 1,526 across the 18 observational. Of the 44 that completed or were terminated, 9 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Cardiocentro Ticino has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
7 of the studies in Myocardial Infarction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT05859620University Hospital, Basel, SwitzerlandImplementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery | 2026-12 |
| NCT04988672Luzerner KantonsspitalOPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction | 2026-12-31 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.
The main questions it aims to answer are:
Researchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical). The AI output is made available to clinicians in real time, prior to diagnostic or therapeutic decisions, to facilitate earlier identification of occlusion myocardial infarction (OMI) and potentially expedite intervention.
Diagnostic Test: AI-assisted ECG interpretation (PMcardio)
Participants will receive standard ECG interpretation without AI support. Clinical decisions regarding diagnosis and treatment will follow usual care pathways, without influence from the AI tool. This arm serves as the comparator to evaluate the added value of AI integration.
Participants in the experimental arm will undergo 12-lead ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical, Slovakia). The AI algorithm analyzes ECG data in real time to detect patterns suggestive of occlusion myocardial infarction (OMI), including cases not meeting traditional ST-elevation myocardial infarction (STEMI) criteria. In the experimental arm, the AI output is provided immediately to the treating clinician and used as an adjunct to standard ECG interpretation to support timely diagnosis and management decisions.
Hierarchical primary endpoint
The primary endpoint of the prospective phase, analysed hierarchically using the unmatched, unstratified win ratio, will be a composite of: * Cardiovascular mortality at 30 days. * Timely treatment of angiographically confirmed TIMI 0-1 occlusions, defined as insertion of the arterial sheath within 120 minutes from randomization. * Time-to-treatment of angiographically confirmed TIMI 0-1 occlusions. * Peak high- hsTnT levels in ng/mL as a surrogate measure of infarct size. Time of coronary intervention will be defined as time from randomisation to insertion of the arterial sheath. Peak hsTnT is defined as the maximum level of hsTnT within 48h from randomization or within 48 hours from intervention if percutaneous coronary intervention took place later than 24 hours from randomization.
Time frame: 30 days
Cardiovascular mortality at 30 days
Cardiovascular mortality at 30 days
Time frame: 30 days
Timely treatment of TIMI 0-1 occlusions
Timely treatment is defined as arterial sheath insertion within 120 minutes of randomization
Time frame: Periprocedural
Time-to-treatment of TIMI 0-1 occlusions
Expressed in minutes from time of randomization
Time frame: Periprocedural
Peak hsTnT levels
Peak hsTnT is defined as the maximum level of hsTnT within 48h from randomization or within 48 hours from intervention if percutaneous coronary intervention took place later than 24 hours from randomization.
Time frame: 48 hours from randomization or intervention
Major adverse cardiovascular events (MACE) at follow-up
Major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, myocardial infarction, or stroke at follow up (30-days, 1 year, 3/5/10 years)
Time frame: up to 10 years
Cardiovascular death at follow-up
Cardiovascular death at follow up (30-days, 1 year, 3/5/10 years)
Time frame: up to 10 years
Myocardial infarction at follow-up
Myocardial infarction at follow up (30-days, 1 year, 3/5/10 years)
Time frame: up to 10 years
Stroke at follow-up
Stroke at follow up (30-days, 1 year, 3/5/10 years)
Time frame: up to 10 years
Infarct Size
• hsTnT area under the curve
Time frame: 48 hours from randomization or intervention
Infarct Size
• Creatine kinase-MB (CK-MB) peak concentration
Time frame: 48 hours from randomization or intervention
Infarct Size
• CK-MB area under the curve
Time frame: 48 hours from randomization or intervention
Time from randomization to antithrombotic therapy
Time from randomization to antithrombotic therapy (expressed in minutes)
Time frame: periprocedural
Time from randomization to coronary angiography
Time from randomization to coronary angiography (expressed in minutes) This outcome will be assessed both in all patients and in patients with OMI according to the different definitions.
Time frame: periprocedural
Angiographic outcomes (restricted to patients undergoing PCI)
* Worst TIMI flow grade post-PCI (0-3) * Worst TIMI thrombus grade post-PCI (0-5)
Time frame: Periprocedural
Total time spent in the emergency department post-randomization
Total time spent in the emergency department post-randomization
Time frame: periprocedural
Length of hospital stay post-randomization
Length of hospital stay post-randomization (days)
Time frame: up to 30 days
Resource utilization
Number of diagnostic tests and procedures performed post-randomization before coronary angiography, including troponin measurements, transthoracic echocardiography and stress testing
Time frame: periprocedural
Health economic outcomes
These include both direct and indirect costs. Direct costs are defined as medical costs incurred post-randomization during the index hospitalization or emergency department visit, including diagnostics and procedures (e.g., ECG, troponin testing, coronary angiography, PCI), medications and consumables, staff time, and length of stay. Indirect costs, defined as non-medical or societal costs up to 30 days post-randomization, including lost productivity (e.g., time off work for patients or caregivers), transportation to follow-up visits, informal caregiving support, and early rehabilitation services
Time frame: 30 days
Safety (Serious adverse events)
Time frame: up to 10 years
Diagnostic accuracy of AI algorithm
Restricted to patients in the control group: * Sensitivity * Specificity * Positive predictive value (PPV) * Negative predictive value (NPV)
Time frame: periprocedural
Quality of life (EuroQol 5-Dimension 5-Level [EQ-5D-5L] Index Score)
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument at discharge and 30 days post-randomization. The EQ-5D-5L descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five levels of severity. Responses are converted into a single index score using a country-specific value set. The index score typically ranges from values below 0 (worse than death) to 1 (full health), with higher scores indicating better health-related quality of life.
Time frame: up to 30 days
Pre-procedural ECG analysis
Sensitivity analysis of diagnostic accuracy of the AI-algorithm based on the 12-lead ECG recorded immediately prior to the start of coronary angiography, instead of the ECG at presentation.
Time frame: periprocedural
Alternative OMI definitions
Sensitivity analysis of the primary outcome using an alternative definition of OMI: TIMI flow 0-1, or TIMI flow 2-3 in the presence of large thrombus burden (TIMI thrombus grade ≥3).
Time frame: 30 days
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Access criteria: Reasonable request
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 24 months is below that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiocentro Ticino